July 18, 2012
Seoul, July 18, 2012—The International Vaccine Institute (IVI) and the Sabin Vaccine Institute (Sabin) signed a memorandum of understanding (MOU) to form a strategic alliance around research, development and advocacy among other stipulations at IVI headquarters on July 17th.
IVI and Sabin have been at the forefront in efforts to achieve common goals around supporting public health of the world’s poorest people through vaccines. The two organizations undertake research, development and promotion activities for new vaccines particularly for neglected diseases; advocate for global access to vaccines; and forge and maintain strong ties to international agencies.
This strategic alliance will allow both organizations to benefit by complementing their current capabilities, such as focused disease areas and networks. In addition, the two organizations will collaborate to leverage their presence in different geographical regions, IVI in Asia and Africa and Sabin in the U.S. and Latin America.
“I am thrilled to be signing this agreement with Sabin,” said Dr. Christian Loucq, Director-General of IVI “Sabin shares common values with IVI and we look forward to seeking means to promote effective and efficient ways to advocate vaccine development in, and introduction to, developing countries.”
IVI and Sabin have agreed on the following through this MOU: 1) Mutual introduction for product development programs; 2) Joint grant applications for development projects; 3) Joint grant applications for advocacy; 4) Establishment of offices in respective headquarters upon request; 5) Provision of policy presence and education of respective governmental entities where each organization has a strong presence; 6) Collaboration on fundraising; 7) Sharing of resources and personnel in the areas of regulatory affairs and submissions, quality assurance, and contract resource organization inputs.
“The strategic alliance between Sabin and IVI will allow our two organizations to strengthen the core activities that are required to build out a pipeline of vaccines for the world’s poorest communities,” said Michael W. Marine, Chief Executive Officer at Sabin. “We look forward to collaborating with IVI on fundamental organizational priorities, including fundraising and advocacy efforts.”
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established as an initiative of the United Nations Development Programme in 1997, IVI operates as an independent international organization under a treaty signed by 38 countries and the World Health Organization. The Institute conducts research in more than 30 countries of Asia, Africa and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, as well as Japanese encephalitis and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int.
About the Sabin Vaccine Institute
Sabin Vaccine Institute is a non-profit, 501(c)(3) organization of scientists, researchers and advocates dedicated to reducing needless human suffering caused by vaccine-preventable and neglected tropical diseases. Sabin works with governments, leading public and private organizations and academic institutions to provide solutions for some of the world's most pervasive health challenges. Since its founding in 1993 in honor of the oral polio vaccine developer, Dr. Albert B. Sabin, the Institute has been at the forefront of efforts to control, treat and eliminate these diseases by developing new vaccines, advocating the use of existing vaccines and promoting increased access to affordable medical treatments. For more information please visit www.sabin.org
Tae Kyung Byun
Public Awareness/Advocacy Officer